<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Med Paediatr Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Med Paediatr Oncol</journal-id><journal-id journal-id-type="publisher-id">IJMPO</journal-id><journal-title-group><journal-title>Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical &#x00026; Paediatric Oncology</journal-title></journal-title-group><issn pub-type="ppub">0971-5851</issn><issn pub-type="epub">0975-2129</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29200707</article-id><article-id pub-id-type="pmc">5687000</article-id><article-id pub-id-type="publisher-id">IJMPO-38-409b</article-id><article-id pub-id-type="doi">10.4103/ijmpo.ijmpo_125_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letters to Editor</subject></subj-group></article-categories><title-group><article-title>WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yasri</surname><given-names>Sora</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Wiwanitkit</surname><given-names>Viroj</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Joob</surname><given-names>Beuy</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1"><italic>KMT Primary Care Center, Bangkok, Thailand</italic></aff><aff id="aff2"><label>1</label><italic>Wiwanitkit House, Bang Khae, Thailand</italic></aff><aff id="aff3"><label>2</label><italic>Sanitation 1 Medical Academic Center, Bangkok, Thailand</italic></aff><author-notes><corresp id="cor1"><italic><bold>Address for correspondence: </bold> Dr. Sora Yasri, KMT Primary Care Center, Bangkok, Thailand. E-mail: <email xlink:href="sorayasri@outlook.co.th">sorayasri@outlook.co.th</email></italic></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2017</year></pub-date><volume>38</volume><issue>3</issue><fpage seq="b">409</fpage><lpage>410</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2017 Indian Journal of Medical and Paediatric Oncology</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Sir,</p><p>The pancreatic cancer is a deadly gastrointestinal cancer. The treatment by chemotherapy is a present cancer therapy option. Gemcitabine is widely used for the management of pancreatic cancer.[<xref rid="ref1" ref-type="bibr">1</xref>] The effect of genetic underlying factor in response to gemcitabine is interesting. Schirmer <italic>et al</italic>. reported that &#x0201c;WWOX rs11644322 represents a major predictive factor in gemcitabine-treated pancreatic cancer. Decreased WWOX expression may interfere with gemcitabine sensitivity.&#x0201d;[<xref rid="ref2" ref-type="bibr">2</xref>] Schirmer <italic>et al</italic>. found that the survival period of the patients decreased in order if they present GG, GA, and AA genotypes, respectively.[<xref rid="ref2" ref-type="bibr">2</xref>] Here, the authors would like to discuss on the finding based on the quantum medicine calculation as previously reported in referenced publications.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>]</p><p>Theoretically, the three genotypes can be successfully expressed, but there will be the difference in degree of expression based on the starting molecular component. In translation, the final amount of product will vary on the variation on molecular weight of genetic component. From calculation, the molecular weight will be N + 302.26, N + 286.26, and N + 270.28, where N is the molecular weight of other nucleotides apart from the variant point, for GG, GA, and AA genotypes, respectively. It can be seen that the variation AA has the lowest amount of starting molecular component; hence, it might result in the lowest amount of final product which further implies the lowest amount of successful bringing of derived translated product and drug, gemcitabine.</p><sec disp-level="2" id="sec2-1"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec disp-level="2" id="sec2-2" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></body><back><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>BA</given-names></name><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Salem</surname><given-names>ME</given-names></name></person-group><article-title>Evolving standards of care for resected pancreatic cancer</article-title><source>Clin Adv Hematol Oncol</source><year>2017</year><volume>15</volume><fpage>141</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">28398285</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirmer</surname><given-names>MA</given-names></name><name><surname>L&#x000fc;ske</surname><given-names>CM</given-names></name><name><surname>Roppel</surname><given-names>S</given-names></name><name><surname>Schaudinn</surname><given-names>A</given-names></name><name><surname>Zimmer</surname><given-names>C</given-names></name><name><surname>Pfl&#x000fc;ger</surname><given-names>R</given-names></name><etal/></person-group><article-title>Relevance of Sp binding site polymorphism in WWOX for treatment outcome in pancreatic cancer</article-title><source>J Natl Cancer Inst</source><year>2016</year><volume>108</volume><fpage>5</fpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joob</surname><given-names>B</given-names></name><name><surname>Wiwanitkit</surname><given-names>V</given-names></name></person-group><article-title>HSD11B1 rs846908 polymorphisms and tacrolimus concentrations: Quantum chemical analysis and implication in patients with renal transplantation</article-title><source>J Nephropharmacol</source><year>2016</year><volume>6</volume><fpage>19</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">28197525</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joob</surname><given-names>B</given-names></name><name><surname>Wiwanitkit</surname><given-names>V</given-names></name></person-group><article-title>ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1) polymorphism and clopidogrel concentration in acute coronary syndrome: Molecular change can explain the observed therapeutic concentration</article-title><source>Anatol J Cardiol</source><year>2016</year><volume>16</volume><fpage>303</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">27111208</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiwanitkit</surname><given-names>S</given-names></name><name><surname>Wiwanitkit</surname><given-names>V</given-names></name></person-group><article-title>Change in molecular weight due to important pfatp6 and pfmdr1 polymorphisms and susceptibility to antimalarial drug: Possible role of epigenetic phenomenon</article-title><source>Asian Pac J Trop Biomed</source><year>2017</year><volume>7</volume><fpage>181</fpage><lpage>2</lpage></element-citation></ref></ref-list></back></article>